September 18, 2020 PR/Corporate

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer

Recommendation is based on the results of the IMbrave150 study, in which the Tecentriq combination improved overall survival and progression-free survival compared with the previous standard of care Basel, 18 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)... Read more

September 16, 2020 Acad, Gov/Utilities Bio/Pharma/CRO PAI Top-10 PR/Corporate

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs More... Read more

September 15, 2020 PR/Corporate

Luminex Corporation Declares Third Quarter Cash Dividend

AUSTIN, Texas, Sept. 15, 2020 /PRNewswire/ — On September 10, 2020, Luminex Corporation (Nasdaq:LMNX) (the “Company”), announced that its board of directors declared a cash dividend for the third quarter of 2020 of $0.09 per share of common stock payable on October 15, 2020 to stockholders of record as of the close of business September 24, 2020. About Luminex... Read more

September 8, 2020 Lab Top-10 PAI Top-10 PR/Corporate

Bruker Appoints Bonnie H. Anderson to its Board of Directors

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that it has appointed Bonnie H. Anderson to serve on its board of directors, effective as of September 3, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005326/en/ (Photo: Business Wire) Ms. Anderson is Co-Founder, Chairman of the Board and CEO of Veracyte,... Read more

September 8, 2020 Acad, Gov/Utilities Microscopy PR/Corporate

Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients

Immunocompromised transplant patients are at risk of major complications when infected with BK virus cobas BKV test addresses critical need for hospitals and laboratories to have standardised and comparable results across institutions New Breakthrough Device test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus... Read more

September 4, 2020 Acad, Gov/Utilities Liq. Handling & Robotics Microscopy PR/Corporate

Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems

First commercial test for fully automated high throughput systems to detect and differentiate SARS-CoV-2, influenza A virus and/or influenza B virus with a single sample As COVID-19 and influenza infections can hardly be differentiated based on symptoms, healthcare professionals can confidently provide the right diagnosis and best course of treatment for patients Test for use... Read more

September 1, 2020 Environ, Ag./Food & Bev Lab Top-10 PR/Corporate

Danaher Appoints Rainer M. Blair As President And CEO

Danaher Appoints Rainer M. Blair As President And CEO WASHINGTON, Sept. 1, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or “the Company”) announced that the Company’s Board of Directors has implemented its previously disclosed succession plan and appointed Rainer M. Blair as President and Chief Executive Officer and a member of the Board of... Read more

September 1, 2020 Acad, Gov/Utilities Bio/Pharma/CRO Microscopy PR/Corporate

Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS

Detects, confirms and differentiates HIV-1 and HIV-2 infections providing clinicians with critical diagnostic data for personalised management of patients with HIV – from appropriate counseling on disease differences to targeted therapy Supports rapid molecular detection of acute HIV infection, which is critical in curbing further disease transmission Combines confirmatory HIV testing and HIV-1/HIV-2 differentiation into... Read more

August 6, 2020 PR/Corporate

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020

SAN DIEGO–(BUSINESS WIRE)—- $ILMN #ILMN–Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020. Second quarter 2020 results reflect the impact of the global COVID-19 pandemic: Revenue of $633 million, a 25% decrease compared to $838 million in the second quarter of 2019 GAAP net income attributable to... Read more